Mysthera Therapeutics, a Basel, Switzerland-based company developing oral therapeutics to treat complex autoimmune diseases, raised $3.5M in Seed funding.
Forty51 Ventures made the investment.
The company intends to use the funds to advance its portfolio of pre-clinical stage, pan-PIM kinase inhibitors to modulate multi-lineage immune cell functions.
Led by CEO Darren Cunningham, and SVP R&D Dr. Stefan Haak, Mysthera Therapeutics is developing first-in-class, oral therapeutics to treat complex autoimmune diseases. The company’s pipeline includes pre-clinical stage, PIM kinase inhibitors in-licensed from Inflection Biosciences Ltd.
PIM kinases are gateway kinases in multiple immune cell lineages (including B and T effector cells) driving excessive inflammation. Elevated PIM kinase may further contribute to the formation and maintenance of tertiary lymphoid structures (TLS) which are associated with disease severity and progression. PIM kinase inhibition selectively modulates immune cell function in multiple lineages associated with complex disease.
FinSMEs
21/08/2023